CD8+ T cells from Pmel mice express transgenic T cell receptors specific to the gp100 antigen of B16 melanoma, making them a perfect candidate for tumor-specific CD8+ T cells for our adoptive cell therapy treatment. The gene discussed is PMEL; the disease is neoplasm.